US 11,723,988 B2
Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector
Deniz Dalkara, Alfortville (FR); Hanen Khabou, Noisy-le-Grand (FR); José-Alain Sahel, Paris (FR); Thierry Leveillard, Maison-Alfort (FR); and Jens Duebel, Paris (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and SORBONNE UNIVERSITE, Paris (FR)
Appl. No. 16/756,988
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and SORBONNE UNIVERSITÉ, Paris (FR)
PCT Filed Oct. 22, 2018, PCT No. PCT/EP2018/078856
§ 371(c)(1), (2) Date Apr. 17, 2020,
PCT Pub. No. WO2019/077159, PCT Pub. Date Apr. 25, 2019.
Claims priority of application No. 17306430 (EP), filed on Oct. 20, 2017.
Prior Publication US 2021/0268125 A1, Sep. 2, 2021
Int. Cl. A61K 48/00 (2006.01); A61P 27/02 (2006.01); C12N 15/86 (2006.01)
CPC A61K 48/0058 (2013.01) [A61K 48/0075 (2013.01); A61P 27/02 (2018.01); C12N 15/86 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2830/008 (2013.01)] 7 Claims
 
1. A recombinant AAV9-derived vector, comprising:
a VP1 capsid protein comprising SEQ ID NO: 11; and
a polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12.